{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:08:11Z","timestamp":1777777691243,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:00:00Z","timestamp":1793750400000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000165","name":"Division of Chemistry","doi-asserted-by":"publisher","award":["CHE-2045023"],"award-info":[{"award-number":["CHE-2045023"]}],"id":[{"id":"10.13039\/100000165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.chroma.2025.466501","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:09:15Z","timestamp":1761782955000},"page":"466501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A rapid reversed-phase liquid chromatography method for the determination of individual monoclonal antibody content in a co-formulated drug product"],"prefix":"10.1016","volume":"1764","author":[{"given":"Matthew R.","family":"Swoyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deklin","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Felix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron R.","family":"Dipaolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Grinias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin M.","family":"Godinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chroma.2025.466501_bib0001","first-page":"233","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib. Ther."},{"key":"10.1016\/j.chroma.2025.466501_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2302\/kjm.60.37","article-title":"Therapeutic monoclonal antibodies","volume":"60","author":"Yamada","year":"2011","journal-title":"Keio J. Med."},{"key":"10.1016\/j.chroma.2025.466501_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.chroma.2025.466501_bib0004","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.chroma.2025.466501_bib0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.chroma.2025.466501_bib0006","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4161\/mabs.3.4.16615","article-title":"Emerging antibody combinations in oncology","volume":"3","author":"Demarest","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.chroma.2025.466501_bib0007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/antib9030036","article-title":"Characterization of co-formulated high-concentration broadly neutralizing anti-HIV-1 monoclonal antibodies for subcutaneous administration","volume":"9","author":"Sharma","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.chroma.2025.466501_bib0008","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/d41586-017-08702-7","article-title":"The benefits of immunotherapy combinations","volume":"552","author":"Schmidt","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.chroma.2025.466501_bib0009","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/jphp.12731","article-title":"Challenges for the pharmaceutical technical development of protein coformulations","volume":"70","author":"Mueller","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.chroma.2025.466501_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2012.07.001","article-title":"Recombinant antibody mixtures: production strategies and cost considerations","volume":"526","author":"Rasmussen","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.chroma.2025.466501_bib0011","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.biologicals.2016.06.005","article-title":"Determination of critical quality attributes for monoclonal antibodies using quality by design principles","volume":"44","author":"Alt","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.chroma.2025.466501_bib0012","unstructured":"International Conference on harmonisation of technical requirements for registration of pharmaceuticals for Human use (ICH). Specifications: Test Procedures and Acceptance Criteria For Biotechnological\/Biological Products Q6B. 1999. https:\/\/database.ich.org\/sites\/default\/files\/Q6B%20Guideline.pdf."},{"key":"10.1016\/j.chroma.2025.466501_bib0013","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/19420862.2019.1578137","article-title":"Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy","volume":"11","author":"Cao","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.chroma.2025.466501_bib0014","series-title":"Development, Characterization and Stability of Therapeutic Protein Co-Formulations","author":"Krieg","year":"2021"},{"key":"10.1016\/j.chroma.2025.466501_bib0015","series-title":"Methods in Enzymology Volume 463: Guide to Protein Purification","first-page":"73","article-title":"Chapter 8 quantitation of protein","author":"Noble","year":"2009"},{"key":"10.1016\/j.chroma.2025.466501_bib0016","unstructured":"M. Shih, I-Tsung; Salerno, Validating slope spectroscopy methods: a formula for robust measurements. C Technologies, Inc (2008) CWP0802261A. https:\/\/cdn.technologynetworks.com\/TN\/Resources\/PDF\/spwp2.pdf."},{"key":"10.1016\/j.chroma.2025.466501_bib0017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/jps.2600750919","article-title":"Mechanism studies of coomassie blue and silver staining of proteins","volume":"75","author":"de Moreno","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.chroma.2025.466501_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113703","article-title":"A hydrophobic interaction chromatography method suitable for quantitating individual monoclonal antibodies contained in co-formulated drug products","volume":"193","author":"Luo","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0019","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/ac00188a003","article-title":"Analytical potential of protein A for affinity chromatography of polyclonal and monoclonal antibodies","volume":"61","author":"Compton","year":"1989","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2025.466501_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpba.2012.08.024","article-title":"Protein quantitation using various modes of high performance liquid chromatography","volume":"71","author":"Grotefend","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0021","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1080\/10826076.2012.743724","article-title":"A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates","volume":"35","author":"Hong","year":"2012","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.chroma.2025.466501_bib0022","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0021-9673(96)00283-X","article-title":"Fast, reproducible size-exclusion chromatography of biological macromolecules","volume":"743","author":"Ricker","year":"1996","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.chroma.2016.11.056","article-title":"Evaluation of size exclusion chromatography columns packed with sub-3 \u03bcm particles for the analysis of biopharmaceutical proteins","volume":"1498","author":"Goyon","year":"2017","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1738691","article-title":"Analytical characterization of coformulated antibodies as combination therapy","volume":"12","author":"Kim","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.chroma.2025.466501_bib0025","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.1021\/ac901408j","article-title":"Multiproduct high-resolution monoclonal antibody charge variant separations by pH gradient ion-exchange chromatography","volume":"81","author":"Farnan","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2025.466501_bib0026","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jpba.2019.02.024","article-title":"Tuning selectivity in cation-exchange chromatography applied for monoclonal antibody separations, part 1: alternative mobile phases and fine tuning of the separation","volume":"168","author":"Farsang","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpba.2016.04.004","article-title":"Hydrophobic interaction chromatography for the characterization of monoclonal antibodies and related products","volume":"130","author":"Fekete","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0028","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/2472555217711666","article-title":"High-throughput screening and analysis of charge variants of monoclonal antibodies in multiple formulations","volume":"22","author":"Alekseychyk","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.chroma.2025.466501_bib0029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ansa.202200058","article-title":"A protocol for setting-up robust hydrophobic interaction chromatography targeting the analysis of intact proteins and monoclonal antibodies","volume":"3","author":"Ewonde","year":"2022","journal-title":"Anal. Sci. Adv."},{"key":"10.1016\/j.chroma.2025.466501_bib0030","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00216-013-6759-7","article-title":"Comparative study of recent wide-pore materials of different stationary phase morphology, applied for the reversed-phase analysis of recombinant monoclonal antibodies","volume":"405","author":"Fekete","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.chroma.2025.466501_bib0031","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.chroma.2017.01.082","article-title":"Superficially porous particles with 1000 \u00c5 pores for large biomolecule high performance liquid chromatography and polymer size exclusion chromatography","volume":"1489","author":"Wagner","year":"2017","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0032","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/jssc.201200297","article-title":"Impact of mobile phase temperature on recovery and stability of monoclonal antibodies using recent reversed-phase stationary phases","volume":"35","author":"Fekete","year":"2012","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.chroma.2025.466501_bib0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpba.2017.04.004","article-title":"Achievable separation performance and analysis time in current liquid chromatographic practice for monoclonal antibody separations","volume":"141","author":"Fekete","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0034","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpba.2012.06.021","article-title":"Analysis of recombinant monoclonal antibodies by RPLC: toward a generic method development approach","volume":"70","author":"Fekete","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.463207","article-title":"Implementing 1.5 mm internal diameter columns into analytical workflows","volume":"1676","author":"Libert","year":"2022","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2012.03.024","article-title":"New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: theory and applications","volume":"69","author":"Fekete","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0037","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jpba.2018.07.013","article-title":"Development and validation of a (RP)UHPLC-UV-(HESI\/Orbitrap)MS method for the identification and quantification of mixtures of intact therapeutical monoclonal antibodies using a monolithic column","volume":"159","author":"P\u00e9rez-Robles","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2025.466501_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1829338","article-title":"Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics","volume":"12","author":"Chen","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.chroma.2025.466501_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461678","article-title":"Importance of particle pore size in determining retention and selectivity in reversed phase liquid chromatography","volume":"1634","author":"Godinho","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0040","doi-asserted-by":"crossref","first-page":"e5087","DOI":"10.1002\/bmc.5087","article-title":"Fundamental to achieving fast separations with high efficiency: a review of chromatography with superficially porous particles","volume":"35","author":"Luo","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.chroma.2025.466501_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9673(01)94511-X","article-title":"Predicting bandwidth in the high-performance liquid chromatographic separation of large biomolecules. II. A general model for the four common high-performance liquid chromatography methods","volume":"387","author":"Stadalius","year":"1987","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0021-9673(94)01254-C","article-title":"High-speed high-performance liquid chromatography of peptides and proteins","volume":"705","author":"Chen","year":"1995","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0043","series-title":"Introduction to Modern Liquid Chromatography","author":"Snyder","year":"2010"},{"key":"10.1016\/j.chroma.2025.466501_bib0044","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0021-9673(00)00392-7","article-title":"Superficially porous silica microspheres for fast high-performance liquid chromatography of macromolecules","volume":"890","author":"Kirkland","year":"2000","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2025.466501_bib0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jconrel.2020.08.013","article-title":"Advancements in the co-formulation of biologic therapeutics","volume":"327","author":"Chauhan","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chroma.2025.466501_bib0046","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/19420862.2015.1016694","article-title":"An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies","volume":"7","author":"Estep","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.chroma.2025.466501_bib0047","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.xphs.2022.05.014","article-title":"It is never too late for a cocktail - development and analytical characterization of fixed-dose antibody combinations","volume":"111","author":"Krieg","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.chroma.2025.466501_bib0048","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.addr.2006.03.011","article-title":"Formulation and delivery issues for monoclonal antibody therapeutics","volume":"58","author":"Daugherty","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.chroma.2025.466501_bib0049","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrd1695","article-title":"Protein drug stability: a formulation challenge","volume":"4","author":"Frokjaer","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chroma.2025.466501_bib0050","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1021\/acs.analchem.5b01578","article-title":"Direct identification of Rituximab main isoforms and subunit analysis by online selective comprehensive two-dimensional liquid chromatography-mass spectrometry","volume":"87","author":"Stoll","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2025.466501_bib0051","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1021\/acs.analchem.8b00776","article-title":"Development of comprehensive online two-dimensional liquid chromatography\/mass spectrometry using hydrophilic interaction and reversed-phase separations for rapid and deep profiling of therapeutic antibodies","volume":"90","author":"Stoll","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2025.466501_bib0052","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1080\/19420862.2016.1203497","article-title":"Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry","volume":"8","author":"Sorensen","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.chroma.2025.466501_bib0053","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acs.analchem.8b04841","article-title":"Recent developments in two-dimensional liquid chromatography: fundamental improvements for practical applications","volume":"91","author":"Pirok","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2025.466501_bib0054","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1039\/D0AN01963A","article-title":"Multi-dimensional LC-MS: the next generation characterization of antibody-based therapeutics by unified online bottom-up, middle-up and intact approaches","volume":"146","author":"Camperi","year":"2021","journal-title":"Analyst"},{"key":"10.1016\/j.chroma.2025.466501_bib0055","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/biom14080999","article-title":"Charge variants characterization of Co-formulated antibodies by three-dimensional liquid chromatography\u2013Mass spectrometry","volume":"14","author":"Jin","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.chroma.2025.466501_bib0056","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Validation of Analytical Procedures Q2(R2). 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2%28R2%29_Guideline_2023_1130.pdf."}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967325008453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967325008453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:29:45Z","timestamp":1773278985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967325008453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"alternative-id":["S0021967325008453"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2025.466501","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rapid reversed-phase liquid chromatography method for the determination of individual monoclonal antibody content in a co-formulated drug product","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2025.466501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"466501"}}